1. Home
  2. OCG vs GOVX Comparison

OCG vs GOVX Comparison

Compare OCG & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oriental Culture Holding LTD

OCG

Oriental Culture Holding LTD

N/A

Current Price

$1.59

Market Cap

3.3M

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.46

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCG
GOVX
Founded
2018
2001
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.8M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
OCG
GOVX
Price
$1.59
$0.46
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
62.8K
668.0K
Earning Date
05-14-2026
04-15-2026
Dividend Yield
8.57%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.12
52 Week High
$19.29
$4.40

Technical Indicators

Market Signals
Indicator
OCG
GOVX
Relative Strength Index (RSI) 42.08 29.17
Support Level $1.45 $0.14
Resistance Level $1.88 $0.86
Average True Range (ATR) 0.12 0.07
MACD -0.01 -0.01
Stochastic Oscillator 2.50 3.65

Price Performance

Historical Comparison
OCG
GOVX

About OCG Oriental Culture Holding LTD

Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. The company generates revenue through listing service fees, transaction fees, and other revenues collected from traders.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: